79th Scientific Sessions of the American Diabetes Association

IDegLira trumps insulin glargine in maintaining glycaemic control for T2D

Pearl Toh, 20190702190000

Using insulin degludec combined with liraglutide (IDegLira) as initial injectable therapy in patients with type 2 diabetes (T2D) who were uncontrolled on oral antidiabetic drugs significantly delays the need for treatment intensification compared with insulin glargine 100 U/mL (IGlar U100) alone, the DUAL VIII study shows.

Linagliptin, glimepiride equally safe for the heart in CAROLINA

Elvira Manzano, 20190629150000

Cardiovascular (CV) outcomes were similar between the dipeptidyl peptidase 4 (DPP-4) inhibitor linagliptin and the sulfonylurea glimepiride in the CAROLINA* study of patients with early type 2 diabetes (T2D) and increased CV risk.

Could immunotherapy delay T1D diagnosis?

Roshini Claire Anthony, 20190627140302

A 2-week course of the immunotherapy drug teplizumab delayed the onset of type 1 diabetes (T1D) in individuals at high risk for the condition, according to a phase II trial conducted by the TrialNet Study Group and presented at ADA 2019.

Automated insulin delivery improves glycaemic control in T1D

Audrey Abella, 20190626100000

The iLet Bionic Pancreas System can effectively control blood glucose levels in adults with type 1 diabetes (T1D), according to data from the first human study of the device presented at ADA 2019.

TODAY2: Youth-onset T2D more aggressive than adult-onset disease

Elaine Soliven, 20190626070316

Patients with youth-onset type 2 diabetes (T2D) are more likely to have an increased rate of cardiovascular (CV), kidney, eye, nerve, and pregnancy complications as they transition to early adulthood, according to the longest-running TODAY*2 study presented at ADA 2019.

Podcast: Dr Lawrence Leiter expounds on the renal benefits seen with dapagliflozin in DECLARE-TIMI 58

20190626020449

Podcast: Dr Lawrence Leiter expounds on the renal benefits seen with dapagliflozin in DECLARE-TIMI 58

Slideshow: Highlights from the 79th Scientific Sessions of the American Diabetes Association

20190626015759

Slideshow: Highlights from the 79th Scientific Sessions of the American Diabetes Association

New insights from DECLARE-TIMI 58: Dapagliflozin averts CKD progression, renal death in T2D

Elvira Manzano, 20190624005258

The SGLT2* inhibitor dapagliflozin significantly reduced the risk of kidney disease progression or renal death in a large cohort of patients with type 2 diabetes (T2D), according to a sub-analysis of renal data from the phase III DECLARE-TIMI 58** trial reported at ADA 2019.

Antidiabetics charting new territory in renal preservation

Pearl Toh, 20190623150000

Emerging evidence is showing that the two major new classes of antidiabetic drugs — SGLT2* inhibitors and GLP-1** receptor agonists (RAs) — not only confer cardiovascular (CV) benefits to patients with type 2 diabetes (T2D), they also delay the loss of kidney function among these patients, potentially providing nephrologists with an additional tool in their armamentarium for managing patients with chronic kidney disease (CKD) in the future.

CGM valuable in young diabetes patients

Tristan Manalac, 20190622100000

Continuous glucose monitors (CGMs) are valuable tools for controlling type 1 diabetes among children and young adults, as well as for improving patient satisfaction with diabetes care, according to two studies presented in a joint symposium at the recently concluded 79th Scientific Sessions of the American Diabetes Association at the Moscone Convention Center in San Francisco.